Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- Cionic, Inc.
- Study ID
- NCT05964829
- Status
- Recruiting
Conditions
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cionic Neural Sleeve NS-100 — DEVICEThe Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
- Walking Program — BEHAVIORAL15 minutes of walking for 5 days per week for 6 weeks
Study Details
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Key Dates
- Start date
- Sep 4, 2023
- Status verified
- Sep 2025
- Primary completion
- Jun 30, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 14 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: ControlParticipants will follow the walking program.
- Experimental: Functional electrical stimulationParticipants will follow the walking program and receive stimulation assistance during the walking sessions.
Primary Outcome Measure
Change in Gait Speed [ Time Frame: Day 0, Week 6, Week 12 ]
Central Contacts
- Douglas A Wajda, PhD3308837149
- Rebecca Webster, PhD925-788-6649
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cleveland State University | Cleveland | Ohio | 44115 | Douglas A Wajda |
Find similar trials in Cleveland, OH
By condition
By specialty
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPHASE1 · Recruiting · Hoffmann-La Roche · Stanford, California
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisPHASE3 · Recruiting · Bristol-Myers Squibb · Loma Linda, California